Evidence map›Paper›PMID 34646251›Full record

ArticleFrontiers in microbiology2021

The Crossroads of Glycoscience, Infection, and Immunology.

Tanya R McKitrick, Margaret E Ackerman, Robert M Anthony, Clay S Bennett, Michael Demetriou, Gregory A Hudalla, Katharina Ribbeck, Stefan Ruhl, Christina M Woo, Loretta Yang and 3 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Microbiome research reports · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 12 institutions in 1 country.

Tanya R McKitrickNational Center for Functional Glycomics, Harvard Medical School, Boston, MA, United States.
Margaret E AckermanThayer School of Engineering, Dartmouth College, Hanover, NH, United States.
Robert M AnthonyCenter for Immunology and Inflammatory Diseases, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.
Clay S BennettDepartment of Chemistry, Tufts University, Medford, MA, United States.
Michael DemetriouDepartment of Neurology, Microbiology, and Molecular Genetics, University of California, Irvine, Irvine, CA, United States.
Gregory A HudallaJ Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, FL, United States.
Katharina RibbeckDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, United States.
Stefan RuhlDepartment of Oral Biology, University at Buffalo School of Dental Medicine, Buffalo, NY, United States.
Christina M WooDepartment of Chemistry and Chemical Biology, Harvard University, Cambridge, MA, United States.
Loretta YangLectenz Bio, Athens, GA, United States.
Seth J ZostVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN, United States.
Ronald L SchnaarDepartment of Pharmacology, Johns Hopkins University, Baltimore, MD, United States.
Tamara L DoeringDepartment of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, United States.
Harvard University · USDartmouth College · USJohns Hopkins University · USLectenz Bio (United States) · USMassachusetts General Hospital · USMassachusetts Institute of Technology · USTufts University · USUniversity at Buffalo, State University of New York · USUniversity of California, Irvine · USUniversity of Florida · USVanderbilt University Medical Center · USWashington University in St. Louis · US

Funding

Using siglecs and their ligands to treat allergic diseases SALTADU19AI136443 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI PAULSON, JAMES C · 2018 to 2022
$7.6M
Microbial Recognition of Sialic Acid Diversity in the Salivary ProteomeR01DE019807 · NIDCR · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI RUHL, STEFAN HANS-KLAUS · 2010 to 2022
$4.7M
CRYPTOCOCCAL GLYCAN SYNTHESISR01AI135012 · NIAID · WASHINGTON UNIVERSITY · PI DOERING, TAMARA L · 2018 to 2022
$2.5M
Tools to facilitate manipulation of protein-specific glycosylation stoichiometry in cellsU01CA242098 · NCI · HARVARD UNIVERSITY · PI WOO, CHRISTINA · 2019 to 2021
$1.4M
NCI NIH HHS U01 CA242098NIAID NIH HHS R01 AI135012NIAID NIH HHS U19 AI136443NIDCR NIH HHS R01 DE019807
6 · The paper itself

Abstract

Advances in experimental capabilities in the glycosciences offer expanding opportunities for discovery in the broad areas of immunology and microbiology. These two disciplines overlap when microbial infection stimulates host immune responses and glycan structures are central in the processes that occur during all such encounters. Microbial glycans mediate host-pathogen interactions by acting as surface receptors or ligands, functioning as virulence factors, impeding host immune responses, or playing other roles in the struggle between host and microbe. In the context of the host, glycosylation drives cell-cell interactions that initiate and regulate the host response and modulates the effects of antibodies and soluble immune mediators. This perspective reports on a workshop organized jointly by the National Institute of Allergy and Infectious Diseases and the National Institute of Dental and Craniofacial Research in May 2020. The conference addressed the use of emerging glycoscience tools and resources to advance investigation of glycans and their roles in microbe-host interactions, immune-mediated diseases, and immune cell recognition and function. Future discoveries in these areas will increase fundamental scientific understanding and have the potential to improve diagnosis and treatment of infections and immune dysregulation.

Indexed as

glycobiologyglycomedicineglycosciencehost responseimmunityinfectionmicrobial glycans

Identifiers

PMID34646251
PMCPMC8504252
OpenAlexW3203236836

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.